|
|
Flt-3 ligand |
|
Vaxjo ID |
374 |
|
Vaccine Adjuvant Name |
Flt-3 ligand |
|
Adjuvant VO ID |
VO_0005535
|
|
Description |
natural adjuvant that induces a Th1 response |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
"dendritic cell (DC) growth factor, Flt-3 ligand (FL)naturally occurring glycoprotein that stimulates early hematopoietic progenitors via the FLT3 receptor" |
|
Dosage |
20 μg/kg FL |
|
Function |
increases antigen presenting DCs |
| References |
Disis et al., 2002: Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 2002; 99(8); 2845-2850. [PubMed: 11929774].
Nayak et al., 2006: Nayak BP, Sailaja G, Jabbar AM. Augmenting the immunogenicity of DNA vaccines: role of plasmid-encoded Flt-3 ligand, as a molecular adjuvant in genetic vaccination. Virology. 2006; 348(2); 277-288. [PubMed: 16563456].
|
|
